Journal: Frontiers in Pharmacology
Article Title: Gossypetin targets the liver-brain axis to alleviate pre-existing liver fibrosis and hippocampal neuroinflammation in mice
doi: 10.3389/fphar.2024.1385330
Figure Lengend Snippet: CCl 4 induced liver MKK3/6-p38 MAPK activation and inflammation can be effectively suppressed by GTIN. The experimental method is also shown in . (A–C) Liver representative sections and quantitative analysis of P-MKK3/MKK6, P-p38 MAPK, p53 protein IHC staining in each group of mice ( n = 5). (D) Western blot results and quantitative analysis of α-SMA ( n = 4), P-MKK3/MKK6 (n = 3), P-p38 MAPK ( n = 4) and p53 ( n = 3) proteins in mice liver. (E) IL-1α, IL-1β, IL-6, IL-10, TNF-α mRNA expression in each group of mice liver ( n = 3). * p < 0.05 compared to CCl 4 group, ** p < 0.01 compared to CCl 4 group, *** p < 0.001 compared to CCl 4 group, **** p < 0.0001 compared to CCl 4 group, ns means no significant difference compared to CCl 4 group, Scale bar: 50 μm.
Article Snippet: The primary antibodies were Col1a1 (Cell Signaling Technology Cat# 72026, RRID: AB_2904565), α-SMA (Cell Signaling Technology Cat# 19245, RRID: AB_2734735), Phospho-p38 MAPK (Thr180/Tyr182) (P-p38 MAPK, Cell Signaling Technology Cat# 4511 (also 4511S), RRID: AB_2139682), Phospho-MKK3 (Ser189)/MKK6 (Ser207) (P-MKK3/MKK6, Cell Signaling Technology Cat# 12280, RRID: AB_2797868), Tumor protein 53 (p53, Cell Signaling Technology Cat# 2524, RRID:AB_331743), CD68/SR-D1 (CD68, Novus Cat# NB100-683, RRID: AB_2074852), Complement component 3 receptor 3 subunit (CD11b, Thermo Fisher Scientific Cat# MA5-17857, RRID: AB_2539241).
Techniques: Activation Assay, Immunohistochemistry, Western Blot, Expressing